{"DataElement":{"publicId":"6691062","version":"1","preferredName":"Patient Previous Administration Raf Kinase Inhibitor MEK Family Gene Mutation Inhibitor ERK Family Gene Mutation Inhibitor Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"Indication as to whether the patient had previous treatment with a RAF inhibitor, a MEK inhibitor, or an ERK inhibitor.","longName":"PRV_ADMN_RAF_MEK_ERK_INHB","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6689649","version":"1","preferredName":"Patient Previous Administration Raf Kinase Inhibitor MEK Family Gene Mutation Inhibitor ERK Family Gene Mutation Inhibitor Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Occurring prior to something else._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine._Any substance that inhibits Raf Kinase, an enzyme active in signal transduction in the Ras pathway. Inhibition of Raf kinase may result in reduced cell proliferation and cell death._A change in the nucleotide sequence in a MEK family gene._A class of substances that binds to and inhibits the function or activity of a target._A change in the nucleotide sequence in a ERK family gene._A class of substances that binds to and inhibits the function or activity of a target._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:6690946v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6690946","version":"1","preferredName":"Previous Administration Raf Kinase Inhibitor MEK Family Gene Mutation Inhibitor ERK Family Gene Mutation Inhibitor Clinical Trial Eligibility Criteria","preferredDefinition":"Occurring prior to something else.:The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.:Any substance that inhibits Raf Kinase, an enzyme active in signal transduction in the Ras pathway. Inhibition of Raf kinase may result in reduced cell proliferation and cell death.:A change in the nucleotide sequence in a MEK family gene.:A class of substances that binds to and inhibits the function or activity of a target.:A change in the nucleotide sequence in a ERK family gene.:A class of substances that binds to and inhibits the function or activity of a target.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"6690946v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Previous","conceptCode":"C25627","definition":"Occurring prior to something else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Raf Kinase Inhibitor","conceptCode":"C2336","definition":"Any substance that inhibits Raf Kinase, an enzyme active in signal transduction in the Ras pathway. Inhibition of Raf kinase may result in reduced cell proliferation and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"MEK Family Gene Mutation","conceptCode":"C136422","definition":"A change in the nucleotide sequence in a MEK family gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Inhibitor","conceptCode":"C154898","definition":"A class of substances that binds to and inhibits the function or activity of a target.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"ERK Family Gene Mutation","conceptCode":"C136423","definition":"A change in the nucleotide sequence in a ERK family gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Inhibitor","conceptCode":"C154898","definition":"A class of substances that binds to and inhibits the function or activity of a target.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86595CFB-8F1C-1758-E053-F662850AFB39","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8632A34B-5381-3AB2-E053-F662850AB7ED","latestVersionIndicator":"Yes","beginDate":"2019-04-10","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-04-10","modifiedBy":"SPRINGERL","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Has the patient had previous","type":"Preferred Question Text","description":"Has the patient had previous treatment with a RAF inhibitor, a MEK inhibitor, or an ERK inhibitor?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Has the patient had previous treatment with dabrafenib (or another RAF inhibitor), trametinib (or another MEK inhibitor), or an ERK inhibitor?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Has the patient had prior treatment with a pan-RAF inhibitor?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8659A592-ADAE-5870-E053-F662850A5369","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-04-12","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","changeDescription":null,"administrativeNotes":"2023.3.28 AQT added per ticket request CADSR0002221. ak","unresolvedIssues":null,"deletedIndicator":"No"}}